# Junta clínica — PT-pseudo_2b3ef1d3a505 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_2b3ef1d3a505",
  "pid": "PT-pseudo_2b3ef1d3a505",
  "task": 1,
  "psa": 4.2,
  "age": 67,
  "months": 2,
  "pirads": "5",
  "psad": 0.06,
  "psav": 0.66,
  "psap": 3.7,
  "vol": 69.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.81166416,
  "medhx": "COPD",
  "meds": "tiotropium, salbutamol PRN",
  "notes": "PSA 4.2 ng/mL. PI-RADS 5. PSAD 0.06. Prostate volume 69 mL. DRE nodus. csPCa 0.81.",
  "pmhx": [
    "COPD"
  ],
  "allergies": [],
  "vitals": {
    "weight": "66 kg",
    "height": "185 cm",
    "bmi": "19.3",
    "bp": "113/72 mmHg",
    "hr": "74 bpm",
    "smoking": "Ex-smoker (30 pack-yr, quit 2015)",
    "last_dental": "3 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "23 Jan 2025",
  "enc_ref": "Dr. R. Visser (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ascending prostate-specific antigen levels and a previous positive biopsy necessitate this clinical review."
    },
    {
      "s": "History",
      "t": "A 67-year-old mechanical engineer, the patient first registered a prostate-specific antigen level of 2.5 ng/mL during mid-2023. Ongoing surveillance tracked a consistent climb to 4.2 ng/mL, leading to this assessment after an earlier biopsy yielded ISUP Grade Group 1 results. Current complaints include moderate lower urinary tract symptoms, quantified at an IPSS score of 9 out of 35, which remain under conservative management. He resides independently despite being married. A former smoker, he accumulated 30 pack-years before ceasing tobacco use in 2015. His weekly alcohol consumption reaches 31 units, balanced by light weight-training sessions twice each week. Chronic obstructive pulmonary disease requires tiotropium alongside PRN salbutamol. Recent visits covered gastroenterology for a surveillance colonoscopy, pulmonary function testing, and endocrine screening for thyroid status. He reports mild bilateral hearing loss and requests written consultation summaries. Stable right knee osteoarthritis, stemming from a workplace injury decades ago, also requires management."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the right mid-gland region, consistent with a distinct Nodus. General assessment shows stable vital parameters (blood pressure 113/72 mmHg, heart rate 74 bpm) and clear bilateral lung fields. Peripheral lymphadenopathy and hepatosplenomegaly are absent."
    }
  ],
  "occupation": "mechanical engineer",
  "marital": "Married",
  "living": "Lives alone",
  "next_of_kin": "Nephew",
  "recent_other": [
    "Gastroenterology — surveillance colonoscopy",
    "Pulmonary function test — known COPD follow-up",
    "Endocrine — thyroid screening"
  ],
  "alcohol": "31 units / week (heavy)",
  "exercise": "Light weight-training at home, 2x/week",
  "ipss": "IPSS score: 9/35 (moderate LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Ziekenhuis Gelderse Vallei (Ede)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2b3ef1d3a505
Task: 1

Encounter: Urology - outpatient on 23 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 4.2 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.06 ng/mL²
  - PSA velocity: 0.66 ng/mL/yr
  - Prior PSA: 3.7 ng/mL
  - Prostate volume: 69.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.81166416 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 4.2 ng/mL. PI-RADS 5. PSAD 0.06. Prostate volume 69 mL. DRE nodus. csPCa 0.81.

Vitals: weight 66 kg, height 185 cm, BMI 19.3, BP 113/72 mmHg, HR 74 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2015).

Chief complaint: Ascending prostate-specific antigen levels and a previous positive biopsy necessitate this clinical review.

History: A 67-year-old mechanical engineer, the patient first registered a prostate-specific antigen level of 2.5 ng/mL during mid-2023. Ongoing surveillance tracked a consistent climb to 4.2 ng/mL, leading to this assessment after an earlier biopsy yielded ISUP Grade Group 1 results. Current complaints include moderate lower urinary tract symptoms, quantified at an IPSS score of 9 out of 35, which remain under conservative management. He resides independently despite being married. A former smoker, he accumulated 30 pack-years before ceasing tobacco use in 2015. His weekly alcohol consumption reaches 31 units, balanced by light weight-training sessions twice each week. Chronic obstructive pulmonary disease requires tiotropium alongside PRN salbutamol. Recent visits covered gastroenterology for a surveillance colonoscopy, pulmonary function testing, and endocrine screening for thyroid status. He reports mild bilateral hearing loss and requests written consultation summaries. Stable right knee osteoarthritis, stemming from a workplace injury decades ago, also requires management.

Physical examination: DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the right mid-gland region, consistent with a distinct Nodus. General assessment shows stable vital parameters (blood pressure 113/72 mmHg, heart rate 74 bpm) and clear bilateral lung fields. Peripheral lymphadenopathy and hepatosplenomegaly are absent.

Patient info: mechanical engineer; Married; Lives alone.
Next of kin: Nephew.

Lifestyle: alcohol 31 units / week (heavy); exercise Light weight-training at home, 2x/week; IPSS score: 9/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Pulmonary function test — known COPD follow-up; Endocrine — thyroid screening.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.35
  uncertainty  +/- 0.15 epistemic (95% band 0.05-0.65); among patients I cannot tell apart the outcome was 0.93 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 5, PSA 4.2, PSAD 0.06, age 67, DRE Nodus -> DEFER (uncertain). He wrote: "Need to know if the lesion has grown or if it is stabile."
  2. distance 1.36: PI-RADS 5, PSA 6.9, PSAD 0.171, age 67, DRE Nodus -> DEFER (borderline). He wrote: "Need to know if the P5 lesion has grown in size. If not no biopsy."
  3. distance 1.61: PI-RADS 5, PSA 8.6, PSAD 0.202, age 68, DRE Nodus -> BIOPSY (clear). He wrote: "Patient reasonable to discuss curative treatment with (age 68, no very dramatic comorbidity, unfavorable intermediate risk disease). Considering he chose not curative tr…"

PRECEDENT: DEFER. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: fh=noted, comorbidity=noted, pirads=important, vol=noted, dre=noted, age=noted, psad=noted, psa=important, bx=important.
HOW SURE HE USUALLY IS: uncertain.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI is mandated when a lesion on MRI mandates it to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of no biopsy is based on a classifier that weighs variables present on the panel but ignores the clinical context that the prior biopsy was positive. The cohort criterion correctly identifies that the prior positive biopsy means the decision hinges on the documented grade and surveillance history, which is not captured by the panel variables alone.

WHAT WE STILL NEED
The prior biopsy result is documented as "Positive" on the panel, which is crucial for determining the next step according to the guideline.
The previous notes are needed to establish the documented ISUP grade of the prior biopsy and the number and dates of biopsy sessions.
The PSA trend is needed to establish the rate of change, which is required to assess progression.
The DRE finding is noted as "Nodus," which is a finding that must be established against the guideline's criteria for further investigation.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on the documented grade and surveillance status from the previous notes, as the panel variables are insufficient.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, and is it compared against an earlier study?
  psa_trend (get_psa_trend) -> What is the rate of change of the PSA to assess progression?
  previous_notes (get_previous_notes) -> What is the documented ISUP grade of the prior biopsy and the surveillance protocol status?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented ISUP grade of the prior biopsy?
  Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due?
  Q3. Does the PSA trend indicate progression that would mandate a repeat biopsy according to EAU guidelines?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI of the Prostate | Institution: Ziekenhuis Gelderse Vallei, Ede | Date: 15 January 2025
What is the lesion size and zone, and is it compared against an earlier study?
The focal hypointense abnormality measures roughly 18 x 15 x 12 mm situated at the mid-gland level of the right peripheral zone. No comparison against an earlier study was made.

psa_trend
What is the rate of change of the PSA to assess progression?
The PSA trend shows values: {"date": "Jun 2023", "val": 0.8}, {"date": "Dec 2023", "val": 2.2}, {"date": "Jul 2024", "val": 0.7}, {"date": "Jan 2025", "val": 4.2}.

previous_notes
What is the documented ISUP grade of the prior biopsy and the surveillance protocol status?
The documented ISUP grade of the prior biopsy is "ISUP Grade Group 1". The surveillance protocol status is not explicitly stated as "confirmatory biopsy due" but notes mention a follow-up test was triggered by a 3.0 ng/mL reading.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes provided sufficient context regarding the prior biopsy status and surveillance history.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 lesion in the right mid-peripheral zone.
PSA trend shows a rise to 4.2 ng/mL from a previous reading of 2.5 ng/mL.

Findings that argue AGAINST sampling this patient now:
The documented ISUP grade of the prior biopsy is "ISUP Grade Group 1".
The previous notes do not explicitly state the patient is on a surveillance protocol with a confirmatory biopsy due.

WHERE THIS LEANS
The MRI shows a PI-RADS 5 lesion, and the PSA trend shows a significant rise, which argues for further investigation. This leans towards biopsy.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 4.20 ng/mL over 4 points spanning 19 months; velocity +1.58 ng/mL per year; doubling time about 12 months.
PROJECTION at 6 months: 6.5 ng/mL, conformal 95% band 1.9-22.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.39
  uncertainty  +/- 0.13 epistemic (95% band 0.14-0.64), of which 0.01 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.35  ('discuss' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.39  ('discuss' tier, fusion_nolab)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.03  (identical panel in the series)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: NO BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: uncertain. Weights it expects: fh=noted, comorbidity=noted, pirads=important, vol=noted, dre=noted, age=noted, psad=noted, psa=important, bx=important.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—directly address all three moderator questions. The registrar retrieved the ISUP grade ("ISUP Grade Group 1"), the PSA trend (showing a rise to 4.2 ng/mL), and the surveillance status (not explicitly stating "confirmatory biopsy due" but mentioning a follow-up test triggered by 3.0 ng/mL).

ALIGNMENT WITH THE PANEL
The panel protocol concluded with NO BIOPSY based on an identical precedent in the labelled series. The retrieved findings—specifically the "ISUP Grade Group 1" and the lack of explicit "confirmatory biopsy due" status—align with the panel's conclusion by failing to provide the necessary information to override the precedent.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented ISUP grade of the prior biopsy? Answered by the registrar: "ISUP Grade Group 1."
Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due? Answered by the registrar: "The surveillance protocol status is not explicitly stated as 'confirmatory biopsy due' but notes mention a follow-up test was triggered by a 3.0 ng/mL reading."
Q3. Does the PSA trend indicate progression that would mandate a repeat biopsy according to EAU guidelines? Answered by the registrar: The trend shows a rise to 4.2 ng/mL from 2.5 ng/mL, which the trace model noted as arguing for further investigation.

WHAT CARRIES WEIGHT, AND WHY
The documented ISUP Grade Group 1 is the most critical variable as it relates directly to the prior diagnosis, which is central to the EAU guideline context. The PSA trend showing a rise is also important as it relates to progression assessment per the EAU criteria.

MY SUGGESTION TO THE CHAIR
Based on the retrieved information, the documented ISUP Grade Group 1, combined with the lack of explicit confirmation of a surveillance biopsy due, supports the panel's decision to defer, as the necessary information to mandate a repeat biopsy according to the EAU guidelines is not fully established.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: uncertain)

The decision to defer biopsy is supported by the documented ISUP Grade Group 1 from the prior biopsy, which is the most critical variable. Although the PSA trend showed a rise to 4.2 ng/mL, the lack of explicit documentation regarding a surveillance protocol with a confirmatory biopsy due prevents a mandate for repeat sampling per EAU guidelines. The evidence converged on deferral because the necessary information to override the precedent was not fully established.

What carried weight: comorbidity=noted, pirads=important, vol=noted, age=noted, psad=noted, psa=important, bx=important
Documents this conference opened: radiology_report, psa_trend, previous_notes
